209 related articles for article (PubMed ID: 35955851)
1. Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist's Decision on Systemic Therapy in a Real-World Setting.
Erber R; Angeloni M; Stöhr R; Lux MP; Ulbrich-Gebauer D; Pelz E; Bankfalvi A; Schmid KW; Walter RFH; Vetter M; Thomssen C; Mayr D; Klauschen F; Sinn P; Sotlar K; Stering K; Stenzinger A; Wunderle M; Fasching PA; Beckmann MW; Hoffmann O; Kimmig R; Harbeck N; Wuerstlein R; Ferrazzi F; Hartmann A
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955851
[TBL] [Abstract][Full Text] [Related]
2. Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast cancers.
Hequet D; Callens C; Gentien D; Albaud B; Mouret-Reynier MA; Dubot C; Cottu P; Huchon C; Zilberman S; Berseneff H; Foa C; Salmon R; Roulot A; Lerebours F; Salomon A; Ghali N; Morel P; Li Q; Cayre A; Guinebretière JM; Hornberger J; Penault-Llorca F; Rouzier R
PLoS One; 2017; 12(10):e0185753. PubMed ID: 29045452
[TBL] [Abstract][Full Text] [Related]
3. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.
Bastien RR; Rodríguez-Lescure Á; Ebbert MT; Prat A; Munárriz B; Rowe L; Miller P; Ruiz-Borrego M; Anderson D; Lyons B; Álvarez I; Dowell T; Wall D; Seguí MÁ; Barley L; Boucher KM; Alba E; Pappas L; Davis CA; Aranda I; Fauron C; Stijleman IJ; Palacios J; Antón A; Carrasco E; Caballero R; Ellis MJ; Nielsen TO; Perou CM; Astill M; Bernard PS; Martín M
BMC Med Genomics; 2012 Oct; 5():44. PubMed ID: 23035882
[TBL] [Abstract][Full Text] [Related]
4. The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer.
Wuerstlein R; Sotlar K; Gluz O; Otremba B; von Schumann R; Witzel I; Schindlbeck C; Janni W; Schem C; Bauerfeind I; Hasmueller S; Tesch H; Paulenz A; Ghali N; Orujov E; Kates RE; Cowens W; Hornberger J; Pelz E; Harbeck N
Curr Med Res Opin; 2016 Jul; 32(7):1217-24. PubMed ID: 26971372
[TBL] [Abstract][Full Text] [Related]
5. Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER PAM50 assay: a real-world study.
Lopez-Tarruella S; Del Monte-Millán M; Roche-Molina M; Jerez Y; Echavarria Diaz-Guardamino I; Herrero López B; Gamez Casado S; Marquez-Rodas I; Alvarez E; Cebollero M; Massarrah T; Ocaña I; Arias A; García-Sáenz JÁ; Moreno Anton F; Olier Garate C; Moreno Muñoz D; Marrupe D; Lara Álvarez MÁ; Enrech S; Bueno Muiño C; Martín M
Breast Cancer Res Treat; 2024 Jan; 203(1):163-172. PubMed ID: 37773555
[TBL] [Abstract][Full Text] [Related]
6. Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial.
Gluz O; Liedtke C; Huober J; Peyro-Saint-Paul H; Kates RE; Kreipe HH; Hartmann A; Pelz E; Erber R; Mohrmann S; Möbus V; Augustin D; Hoffmann G; Thomssen C; Jänicke F; Kiechle M; Wallwiener D; Kuhn W; Nitz U; Harbeck N
Ann Oncol; 2016 Jun; 27(6):1035-1040. PubMed ID: 27022068
[TBL] [Abstract][Full Text] [Related]
7. PAM50- and immunohistochemistry-based subtypes of breast cancer and their relationship with breast cancer mortality in a population-based study.
Wang L; Li Q; Aushev VN; Neugut AI; Santella RM; Teitelbaum S; Chen J
Breast Cancer; 2021 Nov; 28(6):1235-1242. PubMed ID: 34003448
[TBL] [Abstract][Full Text] [Related]
8. PCA-PAM50 improves consistency between breast cancer intrinsic and clinical subtyping reclassifying a subset of luminal A tumors as luminal B.
Raj-Kumar PK; Liu J; Hooke JA; Kovatich AJ; Kvecher L; Shriver CD; Hu H
Sci Rep; 2019 May; 9(1):7956. PubMed ID: 31138829
[TBL] [Abstract][Full Text] [Related]
9. Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer.
Fernandez-Martinez A; Pascual T; Perrone G; Morales S; de la Haba J; González-Rivera M; Galván P; Zalfa F; Amato M; Gonzalez L; Prats M; Rojo F; Manso L; Paré L; Alonso I; Albanell J; Vivancos A; González A; Matito J; González S; Fernandez P; Adamo B; Muñoz M; Viladot M; Font C; Aya F; Vidal M; Caballero R; Carrasco E; Altomare V; Tonini G; Prat A; Martin M
Oncotarget; 2017 Mar; 8(13):21930-21937. PubMed ID: 28423537
[TBL] [Abstract][Full Text] [Related]
10. Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance.
Kim HK; Park KH; Kim Y; Park SE; Lee HS; Lim SW; Cho JH; Kim JY; Lee JE; Ahn JS; Im YH; Yu JH; Park YH
Cancer Res Treat; 2019 Apr; 51(2):737-747. PubMed ID: 30189722
[TBL] [Abstract][Full Text] [Related]
11. Discordance between PAM50 intrinsic subtyping and immunohistochemistry in South African women with breast cancer.
Dix-Peek T; Phakathi BP; van den Berg EJ; Dickens C; Augustine TN; Cubasch H; Neugut AI; Jacobson JS; Joffe M; Ruff P; Duarte RAB
Breast Cancer Res Treat; 2023 May; 199(1):1-12. PubMed ID: 36867282
[TBL] [Abstract][Full Text] [Related]
12. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay.
Wallden B; Storhoff J; Nielsen T; Dowidar N; Schaper C; Ferree S; Liu S; Leung S; Geiss G; Snider J; Vickery T; Davies SR; Mardis ER; Gnant M; Sestak I; Ellis MJ; Perou CM; Bernard PS; Parker JS
BMC Med Genomics; 2015 Aug; 8():54. PubMed ID: 26297356
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of different molecular typing methods and immune status based on RNA sequencing in HR-positive and HER2-negative early-stage breast cancer.
Ren X; Song Y; Zhang Y; Wu H; Chen L; Pang J; Zhou L; Shen S; Liang Z
BMC Cancer; 2022 May; 22(1):548. PubMed ID: 35568835
[TBL] [Abstract][Full Text] [Related]
15. Subtyping of male breast cancer by PAM50 and immunohistochemistry: a pilot study of a consecutive Danish cohort.
Christensen LG; Lautrup MD; Lyng MB; Möller S; Jylling AMB
APMIS; 2020 Sep; 128(9):523-530. PubMed ID: 32579768
[TBL] [Abstract][Full Text] [Related]
16. Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry.
Wirtz RM; Sihto H; Isola J; Heikkilä P; Kellokumpu-Lehtinen PL; Auvinen P; Turpeenniemi-Hujanen T; Jyrkkiö S; Lakis S; Schlombs K; Laible M; Weber S; Eidt S; Sahin U; Joensuu H
Breast Cancer Res Treat; 2016 Jun; 157(3):437-46. PubMed ID: 27220750
[TBL] [Abstract][Full Text] [Related]
17. PAM50 for prediction of response to neoadjuvant chemotherapy for ER-positive breast cancer.
Ohara AM; Naoi Y; Shimazu K; Kagara N; Shimoda M; Tanei T; Miyake T; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2019 Feb; 173(3):533-543. PubMed ID: 30361874
[TBL] [Abstract][Full Text] [Related]
18. Luminal A versus luminal B breast cancer: MammaTyper mRNA versus immunohistochemical subtyping with an emphasis on standardised Ki67 labelling-based or mitotic activity index-based proliferation assessment.
Finsterbusch K; Decker T; van Diest PJ; Focke CM
Histopathology; 2020 Apr; 76(5):650-660. PubMed ID: 31846096
[TBL] [Abstract][Full Text] [Related]
19. Population-based Study of Prosigna-PAM50 and Outcome Among Postmenopausal Women With Estrogen Receptor-positive and HER2-negative Operable Invasive Lobular or Ductal Breast Cancer.
Lænkholm AV; Jensen MB; Eriksen JO; Roslind A; Buckingham W; Ferree S; Nielsen T; Ejlertsen B
Clin Breast Cancer; 2020 Aug; 20(4):e423-e432. PubMed ID: 32253134
[TBL] [Abstract][Full Text] [Related]
20. Chemosensitivity predicted by BluePrint 80-gene functional subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST).
Whitworth P; Stork-Sloots L; de Snoo FA; Richards P; Rotkis M; Beatty J; Mislowsky A; Pellicane JV; Nguyen B; Lee L; Nash C; Gittleman M; Akbari S; Beitsch PD
Ann Surg Oncol; 2014 Oct; 21(10):3261-7. PubMed ID: 25099655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
